title: Trends in the susceptibility of commonly encountered clinically significant anaerobes and susceptibilities of blood isolates of anaerobes to 16 antimicrobial agents, including fidaxomicin and rifaximin, 2008-2012, northern Taiwan.
abstract: We investigated the antimicrobial resistance trends and profiles of clinical anaerobic isolates in northern Taiwan. Trends in the susceptibility of five commonly encountered clinical anaerobic isolates to seven agents from 2008 to 2012 were measured using the Cochran-Armitage trend test. The minimum inhibitory concentrations (MICs) of 16 antimicrobial agents, including fidaxomicin and rifaximin, against anaerobic blood isolates from two medical centers were determined using the agar dilution method. During the study period, susceptibility data on 11,105 isolates were evaluated. Metronidazole and chloramphenicol retained excellent activities. Around 20-30 % of isolates of Bacteroides and Prevotella species were resistant to ampicillin-sulbactam, cefmetazole, flomoxef, and clindamycin. Of the 507 tested blood isolates, the rates of resistance to commonly used agents were much higher, namely, 16.2 % for amoxicillin-clavulanate, 15.6 % for ampicillin-sulbactam, 24.7 % for cefmetazole, and 36.1 % for clindamycin. Notably, 13.5 % of B. fragilis isolates were resistant to ertapenem. Also, 15.2 % of B. uniformis, 17.2 % of other Bacteroides species, 14.3 % of Prevotella species, and 14 % of Clostridium other than C. perfringens isolates were resistant to moxifloxacin. Cefoperazone-sulbactam was active against most isolates, except for Clostridium species other than perfringens (resistance rate, 18.6 %). Fidaxomicin exerted poor activities against most anaerobes tested (MIC90 of >128 μg/ml for B. fragilis and all isolates), except for C. perfringens (MIC90 of 0.03 μg/ml) and Peptostreptococcus micros (MIC90 of 2 μg/ml). However, rifaximin showed a wide range of susceptibilities against the tested anaerobes (MIC90 of 0.5 μg/ml for B. fragilis). The emergence of resistance to ertapenem and moxifloxacin among bacteremic anaerobes highlights the need for continuous monitoring.
authors.affiliation: Section of Infectious Diseases, Department of Medicine, Taipei Veterans General Hospital and National Yang-Ming University, Taipei, Taiwan.
authors.forename: F D
authors.initials: FD
authors.lastname: Wang
authors.forename: C H
authors.initials: CH
authors.lastname: Liao
authors.forename: Y T
authors.initials: YT
authors.lastname: Lin
authors.forename: W H
authors.initials: WH
authors.lastname: Sheng
authors.forename: P R
authors.initials: PR
authors.lastname: Hsueh
mesh_terms: D000046:Academic Medical Centers; D000617:Aminoglycosides / Q000494:pharmacology*; D000890:Anti-Infective Agents / Q000494:pharmacology*; D016470:Bacteremia / Q000453:epidemiology / Q000382:microbiology*; D001421:Bacteria, Anaerobic / Q000187:drug effects* / Q000302:isolation & purification; D024881:Drug Resistance, Bacterial; D062665:Epidemiological Monitoring; D000077732:Fidaxomicin; D006801:Humans; D008826:Microbial Sensitivity Tests; D012294:Rifamycins / Q000494:pharmacology*; D000078262:Rifaximin; D013624:Taiwan / Q000453:epidemiology
chemical_list: D000617:Aminoglycosides; D000890:Anti-Infective Agents; D012294:Rifamycins; D000078262:Rifaximin; D000077732:Fidaxomicin